HOME | AIMEDBIO
10F, 11F MK TOWER, 67 JEONGUI-RO, SONGPA-GU, SEOUL, KOREA 05835 Tel: (+82) 2-6285-0743 [email protected] 05835 Tel: (+82) 2-6285-0743 [email protected]
启德医药和Aimed Bio合作开发5款创新ADC药物 - Pharmcube
2023年7月4日 · 【中国 苏州】近日，致力于颠覆性技术创新生物偶联技术研发的ADC新药开发引领者启德医药宣布，和韩国生物技术公司Aimed Bio建立战略合作伙伴关系，双方将通过技术 …
Our Company - AIMEDBIO
Founded in 2018 as a spin-off from Samsung Medical Center, AimedBio is a preclinical-stage biotechnology company specializing in the development of antibody-based therapeutics, …
启德医药与Aimed Bio再携手，合作开发5款创新ADC药物（ …
2023年7月5日 · 近日，致力于颠覆性技术创新生物偶联技术研发的ADC新药开发引领者启德医药宣布，和韩国生物技术公司Aimed Bio建立战略合作伙伴关系，双方将通过技术合作，共同开发 …
启德医药与Aimed Bio再携手，合作开发5款创新ADC药物（ …
2023年7月5日 · 近日，致力于颠覆性技术创新生物偶联技术研发的ADC新药开发引领者启德医药宣布，和韩国生物技术公司Aimed Bio建立战略合作伙伴关系， 双方将通过 ...
Pipelines - AIMEDBIO
10F, 11F MK TOWER, 67 JEONGUI-RO, SONGPA-GU, SEOUL, KOREA 05835 Tel: (+82) 2-6285-0743 [email protected]
Aimed Bio Inc. - LinkedIn
Precision Neurology & Neuro-Oncology for Brain Health | AIMEDBIO is a spin-off company from Samsung Medical Center with the sole purpose of pursuing after attainable treatment solutions …
Samsung Biologics joins strategic investment in and pursues a …
2023年9月13日 · Samsung Biologics has joined an equity investment in AimedBio, a Korean biotech company pioneering antibody-drug conjugate (ADC) technology. The investment was …
Aimed Bio Licenses Out Global Rights for FGFR3 ADC Candidate …
2025年1月15日 · Aimed Bio co-developed AMB302 with China-based GeneQuantum and received FDA clearance for a Phase 1 clinical trial in 2023. Preclinical studies demonstrated …
Chinese and Korean biotechs expand ADC collaboration - Fierce …
2023年7月7日 · After joining forces last year to work on an antibody-drug conjugate (ADC) to treat brain cancer, China’s GeneQuantum Healthcare and South Korea’s Aimed Bio are expanding …
- 某些结果已被删除